[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Rasagiline.]
[B01AD01, streptokinase, Rasagiline may increase the orthostatic hypotensive activities of Streptokinase.]
[J01GA01, streptomycin, Rasagiline may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Rasagiline.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01CG01, sulbactam, Rasagiline may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Rasagiline may increase the hypoglycemic activities of Sulfadiazine.]
[J01EC01, sulfamethoxazole, Rasagiline may increase the hypoglycemic activities of Sulfamethoxazole.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, Rasagiline may increase the hypoglycemic activities of Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Rasagiline.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Rasagiline is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Rasagiline is combined with Sulthiame.]
[A10BB04, glibornuride, Rasagiline may increase the hypoglycemic activities of Glibornuride.]
[A10BC01, glymidine, Rasagiline may increase the hypoglycemic activities of Glymidine.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Rasagiline is combined with Azapropazone.]
[N06DA01, tacrine, The metabolism of Rasagiline can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The metabolism of Rasagiline can be decreased when combined with Tamoxifen.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Rasagiline.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Terbutaline is combined with Rasagiline.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Dabigatran etexilate.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N07XX06, tetrabenazine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Tetracaine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N05AE05, lurasidone, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Rasagiline.]
[N04BC07, apomorphine, Rasagiline may increase the orthostatic hypotensive activities of Apomorphine.]
[L04AX02, thalidomide, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Rasagiline can be decreased when combined with Theophylline.]
[P02CA02, thiabendazole, The metabolism of Rasagiline can be decreased when combined with Thiabendazole.]
[R06AD03, thiethylperazine, The risk or severity of extrapyramidal symptoms can be increased when Rasagiline is combined with Thiethylperazine.]
[N05CA19, thiopental, Rasagiline may increase the orthostatic hypotensive activities of Thiopental.]
[N05AB08, thioproperazine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Thioproperazine.]
[N05AC02, thioridazine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Thioridazine.]
[N05AF04, thiothixene, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Thiothixene.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Rasagiline is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Rasagiline is combined with Tiapride.]
[B01AC05, ticlopidine, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Tilidine is combined with Rasagiline.]
[S01ED01, timolol, Rasagiline may increase the hypotensive activities of Timolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[S01AA12, tobramycin, Rasagiline may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Rasagiline may increase the hypoglycemic activities of Tolazamide.]
[M02AX02, tolazoline, Rasagiline may increase the hypotensive activities of Tolazoline.]
[V04CA01, tolbutamide, Rasagiline may increase the hypoglycemic activities of Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Rasagiline.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Rasagiline is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome and seizure can be increased when Rasagiline is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Rasagiline.]
[C01DX11, trapidil, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Trapidil.]
[N06AX05, trazodone, Rasagiline may increase the serotonergic activities of Trazodone.]
[L01XF01, tretinoin, Rasagiline may increase the orthostatic hypotensive activities of Tretinoin.]
[C03DB02, triamterene, Rasagiline may increase the orthostatic hypotensive activities of Triamterene.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Rasagiline.]
[C03AA06, trichlormethiazide, Rasagiline may increase the hypotensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[A16AX12, trientine, Rasagiline may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Trifluoperazine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Rasagiline is combined with Trifluperidol.]
[N05AA05, triflupromazine, The risk or severity of extrapyramidal symptoms can be increased when Rasagiline is combined with Triflupromazine.]
[N04AA01, trihexyphenidyl, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of extrapyramidal symptoms can be increased when Rasagiline is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Rasagiline.]
[C02BA01, trimethaphan, Rasagiline may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N06AA06, trimipramine, Rasagiline may increase the serotonergic activities of Trimipramine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Rasagiline.]
[A03BB01, butylscopolamine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Rasagiline.]
[N06AX02, tryptophan, The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Rasagiline.]
[C09CA09, azilsartan medoxomil, Rasagiline may increase the hypotensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Rasagiline.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be decreased when combined with Rasagiline.]
[L01FX04, ipilimumab, Rasagiline may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Rasagiline may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The serum concentration of Rasagiline can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, Rasagiline may increase the hypoglycemic activities of Linagliptin.]
[B01AD04, urokinase, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Urokinase.]
[S01AA28, vancomycin, Rasagiline may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Ezogabine.]
[B01AF01, rivaroxaban, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Rivaroxaban.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Rasagiline is combined with Indacaterol.]
[B01AC24, ticagrelor, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Ticagrelor.]
[C08DA01, verapamil, Rasagiline may increase the orthostatic hypotensive activities of Verapamil.]
[N06AX09, viloxazine, The risk or severity of hypertension can be increased when Viloxazine is combined with Rasagiline.]
[C04AX07, vincamine, Rasagiline may increase the hypotensive activities of Vincamine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[B01AA03, warfarin, Rasagiline may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[N01AX15, xenon, The risk or severity of adverse effects can be increased when Xenon is combined with Rasagiline.]
[C03BA10, xipamide, Rasagiline may increase the hypotensive activities of Xipamide.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Rasagiline.]
[L01EC01, vemurafenib, The serum concentration of Rasagiline can be increased when it is combined with Vemurafenib.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[B06AC02, icatibant, Rasagiline may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[B01AE01, desirudin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Lepirudin.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01MA13, trovafloxacin, The metabolism of Rasagiline can be decreased when combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Rasagiline is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Rasagiline may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Rasagiline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, Rasagiline may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Rasagiline may increase the hypotensive activities of Atenolol.]
[L03AB11, peginterferon alfa-2a, The metabolism of Rasagiline can be decreased when combined with Peginterferon alfa-2a.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Rasagiline is combined with Atracurium.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Rasagiline is combined with Atropine.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Rasagiline.]
[B03XA04, peginesatide, Rasagiline may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[L04AX01, azathioprine, The metabolism of Rasagiline can be decreased when combined with Azathioprine.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[G04BE10, avanafil, The risk or severity of hypotension can be increased when Avanafil is combined with Rasagiline.]
[M03BX01, baclofen, The risk or severity of hypotension can be increased when Baclofen is combined with Rasagiline.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Rasagiline is combined with Lorcaserin.]
[G04BD12, mirabegron, The risk or severity of hypertension can be increased when Rasagiline is combined with Mirabegron.]
[L02BB04, enzalutamide, Rasagiline may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[L04AA31, teriflunomide, The serum concentration of Rasagiline can be decreased when it is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Defibrotide.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Rasagiline is combined with Octopamine.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Rasagiline.]
[D02BA02, octinoxate, Rasagiline may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Rasagiline.]
[S01GA07, brimonidine, The metabolism of Brimonidine can be decreased when combined with Rasagiline.]
[J01MB04, pipemidic acid, The metabolism of Rasagiline can be decreased when combined with Pipemidic acid.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C08CA13, lercanidipine, Rasagiline may increase the hypotensive activities of Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Rasagiline is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Rasagiline.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Rasagiline.]
[N02CC03, zolmitriptan, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Rasagiline may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Diethyl ether is combined with Rasagiline.]
[G04BE03, sildenafil, The risk or severity of hypotension can be increased when Sildenafil is combined with Rasagiline.]
[V08CA11, gadofosveset, Rasagiline may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[B01AF02, apixaban, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Apixaban.]
[A16AX08, teduglutide, Rasagiline may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, Rasagiline may increase the hypoglycemic activities of Alogliptin.]
[A16AX09, glycerol phenylbutyrate, Rasagiline may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Rasagiline may increase the hypotensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Rasagiline is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Rasagiline is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Rasagiline is combined with Benperidol.]
[A10BK02, canagliflozin, Rasagiline may increase the orthostatic hypotensive activities of Canagliflozin.]
[J01MA15, gemifloxacin, The metabolism of Rasagiline can be decreased when combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The metabolism of Rasagiline can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Rasagiline can be decreased when combined with Tegaserod.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Rasagiline is combined with Insulin detemir.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Rasagiline.]
[A10BX05, pramlintide, Rasagiline may increase the hypoglycemic activities of Pramlintide.]
[L03AA12, ancestim, Rasagiline may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of hypertension can be increased when Celecoxib is combined with Rasagiline.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Rasagiline.]
[N04AC01, benztropine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Rasagiline is combined with Benzydamine.]
[L01EE01, trametinib, Rasagiline may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Rasagiline is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Rasagiline may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, Rasagiline may increase the serotonergic activities of Levomilnacipran.]
[C08EA02, bepridil, Rasagiline may increase the hypotensive activities of Bepridil.]
[C02KX05, riociguat, Rasagiline may increase the hypotensive activities of Riociguat.]
[A10BJ03, lixisenatide, Rasagiline may increase the hypoglycemic activities of Lixisenatide.]
[C02KX04, macitentan, Rasagiline may increase the hypotensive activities of Macitentan.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Rasagiline.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Rasagiline can be decreased when combined with Simeprevir.]
[S01EA03, apraclonidine, Rasagiline may increase the alpha-adrenergic activities of Apraclonidine.]
[J05AP08, sofosbuvir, Rasagiline may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Rasagiline.]
[A10BK01, dapagliflozin, Rasagiline may increase the orthostatic hypotensive activities of Dapagliflozin.]
[C01CA27, droxidopa, Rasagiline may increase the hypertensive activities of Droxidopa.]
[C07AB04, acebutolol, Rasagiline may increase the hypotensive activities of Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Rasagiline is combined with Tasimelteon.]
[L04AA32, apremilast, The metabolism of Rasagiline can be increased when combined with Apremilast.]
[L02BG02, formestane, Rasagiline may decrease the excretion rate of Formestane which could result in a higher serum level.]
[N07CA01, betahistine, The metabolism of Betahistine can be decreased when combined with Rasagiline.]
[S01ED02, betaxolol, Rasagiline may increase the hypotensive activities of Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Argatroban.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C02CC01, bethanidine, Rasagiline may increase the hypotensive activities of Bethanidine.]
[C10AB02, bezafibrate, Rasagiline may increase the hepatotoxic activities of Bezafibrate.]
[A10BJ04, albiglutide, Rasagiline may increase the hypoglycemic activities of Albiglutide.]
[L04AC11, siltuximab, The metabolism of Rasagiline can be increased when combined with Siltuximab.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Vorapaxar.]
[A03BA03, hyoscyamine, Rasagiline may increase the anticholinergic activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Acenocoumarol.]
[L01XH04, belinostat, The metabolism of Rasagiline can be increased when combined with Belinostat.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Rasagiline is combined with Alfaxalone.]
[A10BK03, empagliflozin, Rasagiline may increase the orthostatic hypotensive activities of Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Rasagiline is combined with Olodaterol.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[D11AA01, glycopyrronium, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N05CM19, suvorexant, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of extrapyramidal symptoms can be increased when Rasagiline is combined with Acepromazine.]
[A10BJ05, dulaglutide, Rasagiline may increase the hypoglycemic activities of Dulaglutide.]
[N04AA02, biperiden, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Rasagiline.]
[S03AA06, gentamicin, Rasagiline may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AA01, dicumarol, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Edoxaban.]
[N06AX11, mirtazapine, Rasagiline may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Rasagiline can be increased when combined with Secukinumab.]
[N02BE01, acetaminophen, The metabolism of Rasagiline can be decreased when combined with Acetaminophen.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[A03AA09, difemerine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Tioclomarol.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Eluxadoline.]
[B01AC25, cangrelor, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Cangrelor.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Rasagiline.]
[G02CX02, flibanserin, The metabolism of Flibanserin can be decreased when combined with Rasagiline.]
[N05AX15, cariprazine, The metabolism of Cariprazine can be decreased when combined with Rasagiline.]
[A10BF01, acarbose, Rasagiline may increase the hypoglycemic activities of Acarbose.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Rasagiline is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Rasagiline is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Rasagiline.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Rasagiline is combined with Insulin degludec.]
[N05AB07, acetophenazine, The risk or severity of extrapyramidal symptoms can be increased when Rasagiline is combined with Acetophenazine.]
[V03AB37, idarucizumab, Rasagiline may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01EB04, osimertinib, The serum concentration of Rasagiline can be decreased when it is combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Rasagiline.]
[L01XG03, ixazomib, Rasagiline may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, Rasagiline may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, Rasagiline may increase the hypoglycemic activities of Acetohexamide.]
[M04AB05, lesinurad, Rasagiline may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Rasagiline.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Rasagiline is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Bromazepam.]
[N04BC01, bromocriptine, Rasagiline may increase the hypertensive activities of Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Rasagiline may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rasagiline.]
[N06AA19, amineptin, Rasagiline may increase the serotonergic activities of Amineptine.]
[C08CA01, amlodipine, Rasagiline may increase the hypotensive activities of Amlodipine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Aniracetam.]
[A05AA04, obeticholic acid, The metabolism of Rasagiline can be decreased when combined with Obeticholic acid.]
[C03CA02, bumetanide, Rasagiline may increase the orthostatic hypotensive activities of Bumetanide.]
[N01BB01, bupivacaine, Rasagiline may increase the orthostatic hypotensive activities of Bupivacaine.]
[C07AA19, bupranolol, Rasagiline may increase the hypotensive activities of Bupranolol.]
[N07BC01, buprenorphine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Rasagiline is combined with Buspirone.]
[L01XX27, arsenic trioxide, Rasagiline may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Rasagiline.]
[S01GX07, azelastine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Rasagiline can be increased when combined with Rucaparib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Balsalazide is combined with Rasagiline.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Rasagiline is combined with Bambuterol.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Rasagiline.]
[A06AH05, naldemedine, Rasagiline may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Rasagiline can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Rasagiline is combined with Beclamide.]
[N06BC01, caffeine, The metabolism of Rasagiline can be decreased when combined with Caffeine.]
[C09AA07, benazepril, Rasagiline may increase the hypotensive activities of Benazepril.]
[A10BX06, benfluorex, Rasagiline may increase the hypoglycemic activities of Benfluorex.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Rasagiline.]
[P01CA02, benznidazole, Rasagiline may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Linezolid.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N07XX13, valbenazine, Rasagiline may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Rasagiline can be increased when combined with Infliximab.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Rasagiline is combined with Safinamide.]
[J01MA23, delafloxacin, Rasagiline may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Betrixaban.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Rasagiline can be decreased when combined with Enasidenib.]
[C07AB07, bisoprolol, Rasagiline may increase the hypotensive activities of Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Bitolterol is combined with Rasagiline.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Rasagiline.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N04AA11, bornaprine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[C01DX19, nesiritide, Rasagiline may increase the orthostatic hypotensive activities of Nesiritide.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Rasagiline is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Brotizolam.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Budesonide may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C04AX20, buflomedil, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Rasagiline is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Rasagiline.]
[N06AA15, butriptyline, Rasagiline may increase the serotonergic activities of Butriptyline.]
[A10BJ06, semaglutide, Rasagiline may increase the hypoglycemic activities of Semaglutide.]
[N01BX04, capsaicin, The metabolism of Rasagiline can be increased when combined with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Rasagiline is combined with Vinylbital.]
[R06AX18, acrivastine, Rasagiline may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, Rasagiline may increase the hypotensive activities of Captopril.]
[L02BB05, apalutamide, Rasagiline may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Rasagiline.]
[A03AA03, camylofine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Rasagiline.]
[L03AB06, interferon alfa-n1, The metabolism of Rasagiline can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, Rasagiline may increase the hypotensive activities of Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Rasagiline.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Rasagiline.]
[L04AA37, baricitinib, Rasagiline may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Rasagiline.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01GB14, plazomicin, Rasagiline may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Rasagiline may increase the hypotensive activities of Celiprolol.]
[A16AX14, migalastat, Rasagiline may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Rasagiline is combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Rasagiline.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Rasagiline is combined with Carbromal.]
[A10BB06, carbutamide, Rasagiline may increase the hypoglycemic activities of Carbutamide.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Rasagiline.]
[D08AE05, chloroxylenol, Rasagiline may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Rasagiline is combined with Lornoxicam.]
[R03DA02, oxtriphylline, The metabolism of Rasagiline can be decreased when combined with Oxtriphylline.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Rasagiline.]
[R03BB08, revefenacin, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Rasagiline can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Rasagiline can be decreased when combined with Carmustine.]
[L01EX13, gilteritinib, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Gilteritinib.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Rasagiline is combined with Amifampridine.]
[A06AX05, prucalopride, Rasagiline may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C09AA08, cilazapril, Rasagiline may increase the hypotensive activities of Cilazapril.]
[B01AX07, caplacizumab, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Caplacizumab.]
[B01AC23, cilostazol, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Cilostazol.]
[A03FA08, cinitapride, The metabolism of Cinitapride can be decreased when combined with Rasagiline.]
[P02BX04, triclabendazole, The metabolism of Rasagiline can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Rasagiline.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Rasagiline is combined with Siponimod.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Rasagiline.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Rasagiline is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Rasagiline.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Cloxazolam.]
[C09CA06, candesartan, Rasagiline may increase the hypotensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Rasagiline can be increased when combined with Etanercept.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of extrapyramidal symptoms can be increased when Rasagiline is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C03BX03, cicletanine, Rasagiline may increase the hypotensive activities of Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, Cyclobenzaprine may increase the serotonergic activities of Rasagiline.]
[N07XX11, pitolisant, The metabolism of Rasagiline can be increased when combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Rasagiline.]
[C03AA09, cyclothiazide, Rasagiline may increase the hypotensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Rasagiline is combined with Insulin pork.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Rasagiline.]
[N03AX25, cenobamate, The therapeutic efficacy of Cenobamate can be decreased when used in combination with Rasagiline.]
[A16AX16, givosiran, The serum concentration of Rasagiline can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Rasagiline may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rasagiline.]
[S01XA12, dexpanthenol, Rasagiline may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Rasagiline.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Rasagiline is combined with Lemborexant.]
[N05AD10, lumateperone, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Lumateperone.]
[M01AX21, diacetylrhein, The metabolism of Rasagiline can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The metabolism of Rasagiline can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Rasagiline can be decreased when combined with Osilodrostat.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Rasagiline.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Dutasteride is combined with Rasagiline.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Rasagiline is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Rasagiline.]
[R02AA03, dichlorobenzyl alcohol, Rasagiline may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Rasagiline may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Rasagiline is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Rasagiline.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Rasagiline.]
[M01AH02, rofecoxib, The serum concentration of Rasagiline can be increased when it is combined with Rofecoxib.]
[C08CA16, clevidipine, Rasagiline may increase the orthostatic hypotensive activities of Clevidipine.]
[C01BD07, dronedarone, The risk or severity of hypertension can be increased when Rasagiline is combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Rasagiline is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Rasagiline.]
[C02AA06, methoserpidine, Rasagiline may increase the hypotensive activities of Methoserpidine.]
[A03AA08, dihexyverine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The metabolism of Rasagiline can be decreased when combined with Capmatinib.]
[N04BX04, opicapone, Rasagiline may increase the orthostatic hypotensive activities of Opicapone.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Rasagiline is combined with Dopexamine.]
[G04BD09, trospium, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Rasagiline is combined with Droxicam.]
[V08CA05, mangafodipir, Rasagiline may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Rasagiline is combined with Selpercatinib.]
[B01AE02, lepirudin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Rasagiline is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Rasagiline is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Rasagiline.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Rasagiline.]
[C08CA17, levamlodipine, Rasagiline may increase the hypotensive activities of Levamlodipine.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Remimazolam.]
[N07XX04, sodium oxybate, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L04AC19, satralizumab, The serum concentration of Rasagiline can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Rasagiline is combined with Oliceridine.]
[P01BA01, chloroquine, Chloroquine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C03AA04, chlorothiazide, Rasagiline may increase the hypotensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Rasagiline.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Chlorpromazine.]
[A10BB02, chlorpropamide, Rasagiline may increase the hypoglycemic activities of Chlorpropamide.]
[N05AF03, chlorprothixene, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Chlorprothixene.]
[C03BA04, chlorthalidone, Rasagiline may increase the hypotensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Rasagiline.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Rasagiline is combined with Ethenzamide.]
[N02BA03, choline salicylate, Rasagiline may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Rasagiline is combined with Ethyl loflazepate.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Rasagiline.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Rasagiline is combined with Etofenamate.]
[M01AX25, chondroitin sulfates, Rasagiline may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Rasagiline is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Rasagiline can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, Rasagiline may increase the orthostatic hypotensive activities of Vericiguat.]
[V03AF12, trilaciclib, The metabolism of Rasagiline can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Rasagiline is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Rasagiline.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Rasagiline is combined with Fenbufen.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Rasagiline.]
[C01CA19, fenoldopam, Rasagiline may increase the hypotensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Rasagiline is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Finasteride is combined with Rasagiline.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01MB07, flumequine, The metabolism of Rasagiline can be decreased when combined with Flumequine.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N02BG07, flupirtine, Rasagiline may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of adverse effects can be increased when Rasagiline is combined with Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Rasagiline is combined with Insulin human.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Rasagiline.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Rasagiline can be increased when it is combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Rasagiline may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Rasagiline.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Rasagiline can be decreased when combined with Cinnarizine.]
[J01MB06, cinoxacin, The metabolism of Rasagiline can be decreased when combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The serum concentration of Rasagiline can be increased when it is combined with Ciprofloxacin.]
[L01XA01, cisplatin, Rasagiline may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Rasagiline can be increased when combined with Somapacitan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The metabolism of Rasagiline can be decreased when combined with Fexinidazole.]
[H01AC09, lonapegsomatropin, The metabolism of Rasagiline can be increased when combined with Lonapegsomatropin.]
[V09AB03, ioflupane I-123, Rasagiline may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Rasagiline may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Rasagiline may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, Rasagiline may increase the anticholinergic activities of Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Rasagiline can be decreased when combined with Mefenamic acid.]
[A10BB12, glimepiride, Rasagiline may increase the hypoglycemic activities of Glimepiride.]
[A10BB08, gliquidone, Rasagiline may increase the hypoglycemic activities of Gliquidone.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Rasagiline is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when St. John's Wort is combined with Rasagiline.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Rasagiline.]
[B01AD11, tenecteplase, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Tenecteplase.]
[N01BB10, levobupivacaine, Rasagiline may increase the orthostatic hypotensive activities of Levobupivacaine.]
[L01EJ03, pacritinib, The metabolism of Rasagiline can be decreased when combined with Pacritinib.]
[N06AA04, clomipramine, Rasagiline may increase the serotonergic activities of Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Rasagiline.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Rasagiline.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[A10BX16, tirzepatide, Rasagiline may increase the hypoglycemic activities of Tirzepatide.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Rasagiline.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Rasagiline.]
[N05AH02, clozapine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Clozapine.]
[A10BX01, guar gum, Rasagiline may increase the hypoglycemic activities of Guar gum.]
[A10BK06, sotagliflozin, Rasagiline may increase the hypoglycemic activities of Sotagliflozin.]
[J01GB12, arbekacin, Rasagiline may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Rasagiline.]
[H01AC08, somatrogon, The metabolism of Rasagiline can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Rasagiline may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Rasagiline can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Rasagiline is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Rasagiline.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Rasagiline.]
[M04AC01, colchicine, Rasagiline may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, Rasagiline may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[L04AA13, leflunomide, The serum concentration of Rasagiline can be decreased when it is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Rasagiline.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Rasagiline is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Rasagiline is combined with Ifenprodil.]
[A10BX03, nateglinide, Rasagiline may increase the hypoglycemic activities of Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Rasagiline is combined with Imidazole salicylate.]
[H01AC03, mecasermin, Rasagiline may increase the hypoglycemic activities of Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Rasagiline is combined with Insulin glargine.]
[B01AC10, indobufen, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Rasagiline.]
[J05AB14, valganciclovir, Rasagiline may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Rasagiline may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[V08AB05, iopromide, Rasagiline may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Rasagiline may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Rasagiline may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Rasagiline.]
[A03AX10, isometheptene, Rasagiline may increase the sympathomimetic activities of Isometheptene.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Rasagiline.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Rasagiline is combined with Parecoxib.]
[B01AB12, bemiparin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Bemiparin.]
[S01AD03, acyclovir, The metabolism of Rasagiline can be decreased when combined with Acyclovir.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Rasagiline is combined with Kebuzone.]
[L01EA01, imatinib, The metabolism of Rasagiline can be decreased when combined with Imatinib.]
[C08CA09, lacidipine, Rasagiline may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Rasagiline can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The metabolism of Rasagiline can be decreased when combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Rasagiline is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Rasagiline is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C09AA03, lisinopril, Rasagiline may increase the hypotensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, Rasagiline may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, Rasagiline may increase the hypotensive activities of Manidipine.]
[A03AA04, mebeverine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Medifoxamine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Rasagiline is combined with Mefenorex.]
[R06AD07, mequitazine, Rasagiline may increase the anticholinergic activities of Mequitazine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N04AA03, methixene, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, Rasagiline may increase the hypertensive activities of Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Rasagiline.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Rasagiline is combined with Cyclobarbital.]
[C03DA04, eplerenone, Rasagiline may increase the hypotensive activities of Eplerenone.]
[N05AD03, metylperon, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Melperone.]
[C03AA07, cyclopenthiazide, Rasagiline may increase the hypotensive activities of Cyclopenthiazide.]
[A10BF02, miglitol, Rasagiline may increase the hypoglycemic activities of Miglitol.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Rasagiline.]
[S01XA18, cyclosporine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Rasagiline.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Rasagiline.]
[N06BA07, modafinil, The metabolism of Rasagiline can be increased when combined with Armodafinil.]
[R06AX02, cyproheptadine, Rasagiline may increase the anticholinergic activities of Cyproheptadine.]
[C09AA13, moexipril, Rasagiline may increase the hypotensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Rasagiline is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Rasagiline is combined with Morniflumate.]
[C03XA02, conivaptan, Rasagiline may increase the orthostatic hypotensive activities of Conivaptan.]
[C02AC05, moxonidine, Rasagiline may increase the hypotensive activities of Moxonidine.]
[J05AF10, entecavir, The metabolism of Rasagiline can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The risk or severity of hypotension can be increased when Vardenafil is combined with Rasagiline.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Rasagiline.]
[L01AX04, dacarbazine, The metabolism of Rasagiline can be decreased when combined with Dacarbazine.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Rasagiline.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Rasagiline is combined with Deanol.]
[C02CC04, debrisoquin, Rasagiline may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Rasagiline.]
[M01AX01, nabumetone, The metabolism of Rasagiline can be decreased when combined with Nabumetone.]
[N07BB05, nalmefene, Rasagiline may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Nordazepam.]
[C07AB12, nebivolol, Rasagiline may increase the hypotensive activities of Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N06AX06, nefazodone, Rasagiline may increase the serotonergic activities of Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Niaprazine.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Rasagiline.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Rasagiline.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Rasagiline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Rasagiline.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Rasagiline is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Normethadone is combined with Rasagiline.]
[B01AX05, fondaparinux, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Escitalopram.]
[G04BD08, solifenacin, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Olsalazine is combined with Rasagiline.]
[N06AA01, desipramine, Rasagiline may increase the serotonergic activities of Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Rasagiline.]
[V04CH02, indigo carmine, Rasagiline may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C09XA02, aliskiren, Rasagiline may increase the hypotensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Oxaprozin is combined with Rasagiline.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Rasagiline.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Oxiracetam.]
[N04AA08, dexetimide, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Rasagiline can be decreased when combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Rasagiline can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, Rasagiline may increase the hypertensive activities of Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Rasagiline.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dextromoramide is combined with Rasagiline.]
[N06AB05, paroxetine, Rasagiline may increase the serotonergic activities of Paroxetine.]
[B01AC04, clopidogrel, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Diamorphine is combined with Rasagiline.]
[C01DA05, pentaerythritol tetranitrate, Rasagiline may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Rasagiline.]
[P03AC04, permethrin, Rasagiline may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Rasagiline.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Rasagiline.]
[V03AH01, diazoxide, Rasagiline may increase the hypotensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Rasagiline.]
[N06AA08, dibenzepin, Rasagiline may increase the serotonergic activities of Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Rasagiline.]
[R05DA08, pholcodine, Pholcodine may increase the serotonergic activities of Rasagiline.]
[S01EC02, dichlorphenamide, Rasagiline may increase the orthostatic hypotensive activities of Diclofenamide.]
[S01BC03, diclofenac, The metabolism of Rasagiline can be decreased when combined with Diclofenac.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[A03AA07, dicyclomine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C02DG01, pinacidil, Rasagiline may increase the hypotensive activities of Pinacidil.]
[A10BG03, pioglitazone, Rasagiline may increase the hypoglycemic activities of Pioglitazone.]
[N05AD05, pipamperone, Rasagiline may increase the orthostatic hypotensive activities of Pipamperone.]
[A03AB14, pipenzolate, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Rasagiline can be decreased when combined with Erlotinib.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Pirbuterol is combined with Rasagiline.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Rasagiline is combined with Diethylpropion.]
[C08CA03, isradipine, Rasagiline may increase the hypotensive activities of Isradipine.]
[D07XC04, diflucortolone, Rasagiline may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Rasagiline.]
[C01AA05, digoxin, Rasagiline may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Rasagiline may increase the hypotensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Rasagiline is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Rasagiline.]
[N02AA03, hydromorphone, Rasagiline may increase the serotonergic activities of Hydromorphone.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Rasagiline can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Rasagiline may increase the hypotensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, Rasagiline may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Pramocaine.]
[C08DB01, diltiazem, Rasagiline may increase the hypotensive activities of Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Rasagiline.]
[V03AB09, dimercaprol, Rasagiline may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Rasagiline is combined with Pridinol.]
[R06AB03, dimethindene, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Procaterol is combined with Rasagiline.]
[M02AX03, dimethyl sulfoxide, Dimethyl sulfoxide may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Rasagiline.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Rasagiline.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Rasagiline is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Rasagiline is combined with Proglumetacin.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Rasagiline.]
[R06AA02, diphenhydramine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Rasagiline.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Quazepam.]
[C09AA06, quinapril, Rasagiline may increase the hypotensive activities of Quinapril.]
[B01AC07, dipyridamole, Rasagiline may increase the orthostatic hypotensive activities of Dipyridamole.]
[N06BA11, dexmethylphenidate, Rasagiline may increase the hypertensive activities of Dexmethylphenidate.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Drotrecogin alfa.]
[N06AA23, quinupramine, Rasagiline may increase the serotonergic activities of Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Rasagiline.]
[C09AA05, ramipril, Rasagiline may increase the hypotensive activities of Ramipril.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Rasagiline is combined with Remoxipride.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Rasagiline is combined with Reproterol.]
[S01AX06, resorcinol, Rasagiline may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Rasagiline can be decreased when combined with Rifamycin.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Rasagiline.]
[N05AX08, risperidone, Rasagiline may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Levocetirizine.]
[N01BB09, ropivacaine, Rasagiline may increase the orthostatic hypotensive activities of Ropivacaine.]
[J01MB01, rosoxacin, The metabolism of Rasagiline can be decreased when combined with Rosoxacin.]
[L01EX01, sunitinib, Rasagiline may increase the hypoglycemic activities of Sunitinib.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The metabolism of Rasagiline can be decreased when combined with Bortezomib.]
[G04BE08, tadalafil, Rasagiline may increase the hypotensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Rasagiline.]
[C02KX02, ambrisentan, Rasagiline may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Rasagiline is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypertension can be increased when Salmeterol is combined with Rasagiline.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C01CA07, dobutamine, Rasagiline may increase the hypertensive activities of Dobutamine.]
[A03FA03, domperidone, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Rasagiline is combined with Domperidone.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Dopamine is combined with Rasagiline.]
[N06AA16, dothiepin, Rasagiline may increase the serotonergic activities of Dosulepin.]
[R07AB01, doxapram, Rasagiline may increase the hypertensive activities of Doxapram.]
[N06AA12, doxepin, Rasagiline may increase the serotonergic activities of Doxepin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Rasagiline.]
[N06AB06, sertraline, The risk or severity of serotonin syndrome can be increased when Sertraline is combined with Rasagiline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Rasagiline.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Rasagiline.]
[A08AA10, sibutramine, Rasagiline may increase the serotonergic activities of Sibutramine.]
[A12CA02, sodium sulfate, Rasagiline may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Rasagiline may increase the hypotensive activities of Spirapril.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Rasagiline is combined with Sultopride.]
[N02CC01, sumatriptan, The metabolism of Sumatriptan can be decreased when combined with Rasagiline.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C07AB13, talinolol, Rasagiline may increase the hypotensive activities of Talinolol.]
[J01MA05, temafloxacin, The metabolism of Rasagiline can be decreased when combined with Temafloxacin.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Rasagiline.]
[G04CA03, terazosin, Rasagiline may increase the hypotensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Rasagiline can be decreased when combined with Terbinafine.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Rasagiline is combined with Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Rasagiline is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Rasagiline is combined with Thiopropazate.]
[G04BD01, emepronium, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Tianeptine is combined with Rasagiline.]
[C09AA02, enalapril, Rasagiline may increase the hypotensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Rasagiline is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Rasagiline is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Atomoxetine.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Rasagiline.]
[C03CA04, torsemide, Rasagiline may increase the hypotensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Rasagiline is combined with Tramazoline.]
[C09AA10, trandolapril, Rasagiline may increase the hypotensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Rasagiline is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Rasagiline is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Rasagiline is combined with Triclofos.]
[A03AB08, tridihexethyl, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[B01AC18, triflusal, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Triflusal.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Rasagiline.]
[N04AA12, tropatepine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[C05CA04, troxerutin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Troxerutin.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Rasagiline is combined with Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Rasagiline.]
[C02CA06, urapidil, Rasagiline may increase the hypotensive activities of Urapidil.]
[J01MA04, enoxacin, The serum concentration of Rasagiline can be increased when it is combined with Enoxacin.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Rasagiline is combined with Veralipride.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Ephedrine is combined with Rasagiline.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Rasagiline.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Venlafaxine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Rasagiline is combined with Xamoterol.]
[S01GA03, xylometazoline, Rasagiline may increase the hypertensive activities of Xylometazoline.]
[C08CA12, mepirodipine, Rasagiline may increase the orthostatic hypotensive activities of Barnidipine.]
[S01EA01, epinephrine, Rasagiline may increase the hypertensive activities of Epinephrine.]
[C09AA15, zofenopril, Rasagiline may increase the hypotensive activities of Zofenopril.]
[N05CF02, zolpidem, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Rasagiline is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Rasagiline.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Rasagiline is combined with Insulin glulisine.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Rasagiline is combined with Zopiclone.]
[N05AX11, zotepine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Zotepine.]
[B01AD03, anistreplase, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Anistreplase.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C02AC02, guanfacine, Rasagiline may increase the hypotensive activities of Guanfacine.]
[B01AC11, iloprost, Rasagiline may increase the orthostatic hypotensive activities of Iloprost.]
[C01BG01, moricizine, The risk or severity of extrapyramidal symptoms can be increased when Rasagiline is combined with Moricizine.]
[G02AB03, ergonovine, Rasagiline may increase the hypertensive activities of Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Rasagiline.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be decreased when combined with Rasagiline.]
[L03AX05, pidotimod, Rasagiline may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Rasagiline.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Rasagiline can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Rasagiline can be decreased when combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Rasagiline can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C01CA15, gepefrine, Rasagiline may increase the hypertensive activities of Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Rasagiline.]
[L02AA03, ethinyl estradiol, The metabolism of Rasagiline can be decreased when combined with Ethinylestradiol.]
[V03AF05, amifostine, Rasagiline may increase the orthostatic hypotensive activities of Amifostine.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N04AA05, profenamine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Rasagiline.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Rasagiline.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Rasagiline.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Rasagiline.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Rasagiline is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Rasagiline.]
[L01CB01, etoposide, The metabolism of Rasagiline can be decreased when combined with Etoposide.]
[N05AE03, sertindole, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Sertindole.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[R06AX12, terfenadine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Rasagiline is combined with Bupropion.]
[N06AB08, fluvoxamine, The serum concentration of Rasagiline can be increased when it is combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Rasagiline can be decreased when combined with Tocainide.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Rasagiline may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Dextran.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[A02BA03, famotidine, The metabolism of Rasagiline can be decreased when combined with Famotidine.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Rasagiline can be increased when combined with Albendazole.]
[C08CA02, felodipine, Rasagiline may increase the hypotensive activities of Felodipine.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Rasagiline.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Fenoterol is combined with Rasagiline.]
[N02AB03, fentanyl, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Salbutamol is combined with Rasagiline.]
[B01AD05, plasmin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Fibrinolysin.]
[L01BB06, clofarabine, Rasagiline may increase the orthostatic hypotensive activities of Clofarabine.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[G04BD02, flavoxate, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Rasagiline can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Rasagiline is combined with Floctafenine.]
[J02AC01, fluconazole, Fluconazole may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Flunitrazepam.]
[N06AA14, melitracen, Rasagiline may increase the serotonergic activities of Melitracen.]
[V03AZ01, ethanol, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[L01BC02, fluorouracil, The metabolism of Rasagiline can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Fluoxetine.]
[N05AF01, flupenthixol, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Flupentixol.]
[N05AB02, fluphenazine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Rasagiline.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Rasagiline.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Rasagiline is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Rasagiline can be decreased when combined with Flutamide.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Rasagiline.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Rasagiline is combined with Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Rasagiline is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Rasagiline.]
[C03CA01, furosemide, Rasagiline may increase the hypotensive activities of Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Rasagiline is combined with Eszopiclone.]
[N05AL05, amisulpride, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Gallamine.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Rasagiline.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Rasagiline is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Rasagiline can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, Rasagiline may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[L01EA02, dasatinib, The metabolism of Rasagiline can be decreased when combined with Dasatinib.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Rasagiline.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Rasagiline.]
[A10BJ02, liraglutide, Rasagiline may increase the hypoglycemic activities of Liraglutide.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Rasagiline is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Rasagiline.]
[A10BB01, glyburide, Rasagiline may increase the hypoglycemic activities of Glyburide.]
[A10BB09, gliclazide, Rasagiline may increase the hypoglycemic activities of Gliclazide.]
[A10BB07, glipizide, Rasagiline may increase the hypoglycemic activities of Glipizide.]
[N05CM18, dexmedetomidine, Rasagiline may increase the orthostatic hypotensive activities of Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Rasagiline is combined with Glutethimide.]
[C05AE01, nitroglycerin, Rasagiline may increase the hypotensive activities of Nitroglycerin.]
[C02CA04, doxazosin, Rasagiline may increase the hypotensive activities of Doxazosin.]
[L01EX02, sorafenib, The metabolism of Rasagiline can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, Rasagiline may increase the hypotensive activities of Esmolol.]
[M01CB04, aurothioglucose, Rasagiline may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Rasagiline may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Fluindione.]
[C09AA09, fosinopril, Rasagiline may increase the hypotensive activities of Fosinopril.]
[S01EX01, guanethidine, Rasagiline may increase the hypotensive activities of Guanethidine.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Rasagiline.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Rasagiline.]
[N05AH04, quetiapine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Quetiapine.]
[N06BX13, idebenone, Rasagiline may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Rasagiline is combined with Insulin aspart.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Rasagiline is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Rasagiline is combined with Allobarbital.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C09CA01, losartan, Rasagiline may increase the hypotensive activities of Losartan.]
[S01XA14, heparin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Heparin.]
[G03DC01, allylestrenol, Rasagiline may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Rasagiline.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[L01XX03, altretamine, Altretamine may increase the orthostatic hypotensive activities of Rasagiline.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Rasagiline.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Rasagiline is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Rasagiline can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, Rasagiline may increase the hypotensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Nimesulide.]
[C09AA04, perindopril, Rasagiline may increase the hypotensive activities of Perindopril.]
[C02DB02, hydralazine, Rasagiline may increase the hypotensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Rasagiline may increase the hypotensive activities of Hydrochlorothiazide.]
[R05DA03, hydrocodone, Rasagiline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, Rasagiline may increase the hypotensive activities of Hydroflumethiazide.]
[B05XA17, potassium acetate, Rasagiline may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[G04BD06, propiverine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Rasagiline is combined with Prothipendyl.]
[B05AA07, hetastarch, Rasagiline may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Rasagiline.]
[C02AC06, rilmenidine, Rasagiline may increase the hypotensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Ibuprofen is combined with Rasagiline.]
[B05XA08, sodium acetate, Rasagiline may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Sodium citrate.]
[L01AA06, ifosfamide, Ifosfamide may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[H01AC02, somatrem, The metabolism of Rasagiline can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Rasagiline.]
[N06AA02, imipramine, Rasagiline may increase the serotonergic activities of Imipramine.]
[L01CD01, paclitaxel, Rasagiline may increase the orthostatic hypotensive activities of Paclitaxel.]
[R01AD07, tixocortol, Rasagiline may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, Rasagiline may increase the orthostatic hypotensive activities of Tizanidine.]
[L01CE01, topotecan, Topotecan may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C03BA11, indapamide, Rasagiline may increase the hypotensive activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Rasagiline.]
[C02CA02, indoramin, Rasagiline may increase the hypotensive activities of Indoramin.]
[A11HA07, inositol, Rasagiline may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The metabolism of Rasagiline can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Rasagiline can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, Rasagiline may increase the serotonergic activities of Milnacipran.]
[A03AA30, piperidolate, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, Varenicline may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Articaine.]
[A10BH01, sitagliptin, Rasagiline may increase the hypoglycemic activities of Sitagliptin.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Rasagiline.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Rasagiline.]
[R06AE01, buclizine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, Rasagiline may increase the hypoglycemic activities of Vildagliptin.]
[L01XX35, anagrelide, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Anagrelide.]
[C07AA01, alprenolol, Rasagiline may increase the hypotensive activities of Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The metabolism of Rasagiline can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, Rasagiline may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, Rasagiline may increase the serotonergic activities of Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Rasagiline is combined with Iproniazid.]
[J05AB13, penciclovir, The metabolism of Rasagiline can be decreased when combined with Penciclovir.]
[N05AA07, chlorproethazine, The risk or severity of extrapyramidal symptoms can be increased when Rasagiline is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Rasagiline.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Rasagiline.]
[C09AA16, imidapril, Rasagiline may increase the hypotensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Rasagiline.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Rasagiline.]
[J04AC01, isoniazid, The metabolism of Rasagiline can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Rasagiline may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Isoprenaline is combined with Rasagiline.]
[A10BJ01, exenatide, Rasagiline may increase the hypoglycemic activities of Exenatide.]
[C01DA14, isosorbide mononitrate, Rasagiline may increase the orthostatic hypotensive activities of Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, Rasagiline may increase the orthostatic hypotensive activities of Isosorbide dinitrate.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C04AA01, isoxsuprine, Rasagiline may increase the orthostatic hypotensive activities of Isoxsuprine.]
[B01AE06, bivalirudin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Bivalirudin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Rasagiline.]
[S01AA24, kanamycin, Rasagiline may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The metabolism of Rasagiline can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Rasagiline can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Rasagiline.]
[C02KD01, ketanserin, Rasagiline may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Rasagiline can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Ketoprofen is combined with Rasagiline.]
[V03AC03, deferasirox, The serum concentration of Rasagiline can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Rasagiline can be increased when combined with Abatacept.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Arbutamine is combined with Rasagiline.]
[N04BC09, rotigotine, Rasagiline may increase the sedative activities of Rotigotine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01MB02, nalidixic acid, The metabolism of Rasagiline can be decreased when combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Rasagiline is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Rasagiline may increase the hypotensive activities of Labetalol.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Rasagiline.]
[C02AA05, deserpidine, Rasagiline may increase the hypotensive activities of Deserpidine.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Rasagiline is combined with Lacosamide.]
[C03CC01, ethacrynic acid, Rasagiline may increase the orthostatic hypotensive activities of Etacrynic acid.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Rasagiline is combined with Levodopa.]
[S02DA01, lidocaine, The metabolism of Rasagiline can be decreased when combined with Lidocaine.]
[S01AA21, amikacin, Rasagiline may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Rasagiline can be increased when combined with Armodafinil.]
[C03DB01, amiloride, Rasagiline may increase the orthostatic hypotensive activities of Amiloride.]
[N02CA07, lisuride, The metabolism of Lisuride can be decreased when combined with Rasagiline.]
[N06AA07, lofepramine, Rasagiline may increase the serotonergic activities of Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Rasagiline.]
[N05AH01, loxapine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Loxapine.]
[B05XA11, magnesium chloride, Rasagiline may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Rasagiline may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Rasagiline can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, Rasagiline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[V04CX04, mannitol, Rasagiline may increase the orthostatic hypotensive activities of Mannitol.]
[N06AA21, maprotiline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Rasagiline.]
[C02BB01, mecamylamine, Rasagiline may increase the hypotensive activities of Mecamylamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Rasagiline.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Rasagiline.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Medazepam.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Dalteparin.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Rasagiline.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N02AB02, meperidine, The risk or severity of serotonin syndrome and opioid toxicity can be increased when Rasagiline is combined with Meperidine.]
[C01CA11, mephentermine, Rasagiline may increase the hypertensive activities of Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Rasagiline.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Rasagiline.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Rasagiline.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Rasagiline.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Meptazinol is combined with Rasagiline.]
[G04BX16, tiopronin, Rasagiline may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Rasagiline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Mesoridazine.]
[N05AX13, paliperidone, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Paliperidone.]
[C01CA09, metaraminol, Rasagiline may increase the hypertensive activities of Metaraminol.]
[A10BA02, metformin, Rasagiline may increase the hypoglycemic activities of Metformin.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Rasagiline.]
[N07BC02, methadone, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Methadone.]
[N06BA03, methamphetamine, Rasagiline may increase the hypertensive activities of Metamfetamine.]
[A03AB07, methantheline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Rasagiline is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Rasagiline is combined with Methaqualone.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Rasagiline.]
[S01EC05, methazolamide, Rasagiline may increase the orthostatic hypotensive activities of Methazolamide.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Rasagiline can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Rasagiline may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Rasagiline.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Rasagiline.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Rasagiline is combined with Ziconotide.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, Rasagiline may increase the hypertensive activities of Methoxamine.]
[D05BA02, methoxsalen, The metabolism of Rasagiline can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Rasagiline.]
[C03AA08, methyclothiazide, Rasagiline may increase the orthostatic hypotensive activities of Methyclothiazide.]
[C02AB01, methyldopa, Rasagiline may decrease the hypotensive activities of Methyldopa.]
[V04CG05, methylene blue, Rasagiline may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Rasagiline.]
[R03DA05, aminophylline, The metabolism of Rasagiline can be decreased when combined with Aminophylline.]
[N06BA04, methylphenidate, Rasagiline may increase the hypertensive activities of Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Rasagiline.]
[G03EK01, methyltestosterone, Rasagiline may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Rasagiline.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Rasagiline.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Rasagiline is combined with Metoclopramide.]
[C03BA08, metolazone, Rasagiline may increase the hypotensive activities of Metolazone.]
[C07AB02, metoprolol, Rasagiline may increase the hypotensive activities of Metoprolol.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Rasagiline can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Rasagiline is combined with Mianserin.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Rasagiline.]
[B01AB07, parnaparin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Parnaparin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Rasagiline.]
[C01CA17, midodrine, Rasagiline may increase the hypertensive activities of Midodrine.]
[G03XB01, mifepristone, Rasagiline may increase the hypoglycemic activities of Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Tinzaparin.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C09CA03, valsartan, Rasagiline may increase the hypotensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Rasagiline.]
[D11AX01, minoxidil, Rasagiline may increase the hypotensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, Rasagiline may increase the hypertensive activities of Lisdexamfetamine.]
[N05AE02, molindone, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Molindone.]
[L03AC01, aldesleukin, Rasagiline may increase the orthostatic hypotensive activities of Aldesleukin.]
[C01BD01, amiodarone, The serum concentration of Rasagiline can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, Rasagiline may increase the serotonergic activities of Amitriptyline.]
[N02AA01, morphine, Rasagiline may increase the analgesic activities of Morphine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Rasagiline.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Rasagiline can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Rasagiline.]
[G04BA01, ammonium chloride, Rasagiline may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Rasagiline.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Rasagiline.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Rasagiline.]
[R03BB01, ipratropium bromide, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, Rasagiline may increase the serotonergic activities of Amoxapine.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Rasagiline.]
[L03AB08, interferon beta-1b, The metabolism of Rasagiline can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, Rasagiline may increase the hypotensive activities of Nadolol.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N04BC04, ropinirole, Rasagiline may increase the sedative activities of Ropinirole.]
[J01CF06, nafcillin, The metabolism of Rasagiline can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Rasagiline is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Rasagiline.]
[V03AB15, naloxone, Naloxone may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Rasagiline.]
[L04AC03, anakinra, The metabolism of Rasagiline can be increased when combined with Anakinra.]
[S01GA01, naphazoline, Rasagiline may increase the hypertensive activities of Naphazoline.]
[N06BA01, amphetamine, Rasagiline may increase the hypertensive activities of Amphetamine.]
[M02AA12, naproxen, The metabolism of Rasagiline can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, Rasagiline may increase the hypoglycemic activities of Troglitazone.]
[N06AX21, duloxetine, The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Duloxetine.]
[N04BX01, tolcapone, Rasagiline may increase the orthostatic hypotensive activities of Tolcapone.]
[S03AA01, neomycin, Rasagiline may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Rasagiline.]
[A10BX02, repaglinide, Rasagiline may increase the hypoglycemic activities of Repaglinide.]
[C01CX08, levosimendan, Rasagiline may increase the orthostatic hypotensive activities of Levosimendan.]
[B01AC17, tirofiban, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Tirofiban.]
[N05AX14, iloperidone, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Iloperidone.]
[J02AA01, amphotericin B, Rasagiline may increase the orthostatic hypotensive activities of Amphotericin B.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[L03AX16, plerixafor, Rasagiline may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Rasagiline may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Rasagiline may increase the serotonergic activities of Desvenlafaxine.]
[C09CA07, telmisartan, Rasagiline may increase the hypotensive activities of Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C01CE01, inamrinone, Rasagiline may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Rasagiline is combined with Nialamide.]
[C08CA04, nicardipine, Rasagiline may increase the hypotensive activities of Nicardipine.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Nicergoline is combined with Rasagiline.]
[P02DA01, niclosamide, The metabolism of Rasagiline can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, Rasagiline may increase the orthostatic hypotensive activities of Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Rasagiline is combined with Niflumic acid.]
[V03AB22, amyl nitrite, Rasagiline may increase the orthostatic hypotensive activities of Amyl Nitrite.]
[C08CA06, nimodipine, Rasagiline may increase the hypotensive activities of Nimodipine.]
[C08CA07, nisoldipine, Rasagiline may increase the hypotensive activities of Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Nitrazepam.]
[C08CA08, nitrendipine, Rasagiline may increase the hypotensive activities of Nitrendipine.]
[R07AX01, nitric oxide, Rasagiline may increase the orthostatic hypotensive activities of Nitric Oxide.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Rasagiline.]
[N04BC05, pramipexole, Rasagiline may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Rasagiline may increase the hypotensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Rasagiline.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Nomifensine.]
[C01CA03, norepinephrine, Rasagiline may increase the hypertensive activities of Norepinephrine.]
[S01AE02, norfloxacin, The metabolism of Rasagiline can be decreased when combined with Norfloxacin.]
[C02KX01, bosentan, Rasagiline may increase the hypotensive activities of Bosentan.]
[N06AA10, nortriptyline, Rasagiline may increase the serotonergic activities of Nortriptyline.]
[B01AC16, eptifibatide, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Eptifibatide.]
[L03AB07, interferon beta-1a, The metabolism of Rasagiline can be decreased when combined with Interferon beta-1a.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Rasagiline is combined with Nylidrin.]
[B01AB08, reviparin, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Reviparin.]
[L04AC04, rilonacept, The metabolism of Rasagiline can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Rasagiline can be increased when combined with Omeprazole.]
[N06AA05, opipramol, Rasagiline may increase the serotonergic activities of Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Opium is combined with Rasagiline.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Rasagiline.]
[B01AD07, reteplase, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Ancrod.]
[G04CA02, tamsulosin, Rasagiline may increase the orthostatic hypotensive activities of Tamsulosin.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Rasagiline.]
[C07AA02, oxprenolol, Rasagiline may increase the hypotensive activities of Oxprenolol.]
[N02AA05, oxycodone, Rasagiline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Rasagiline is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The serum concentration of Oxymetazoline can be increased when it is combined with Rasagiline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Rasagiline.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Rasagiline is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Danaparoid.]
[N02AX06, tapentadol, The risk or severity of adverse effects can be increased when Tapentadol is combined with Rasagiline.]
[M03AC01, pancuronium, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[J04AB30, capreomycin, Rasagiline may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, Rasagiline may increase the orthostatic hypotensive activities of Papaverine.]
[N05CC05, paraldehyde, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Pargyline.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01MA03, pefloxacin, The metabolism of Rasagiline can be decreased when combined with Pefloxacin.]
[G04BD11, fesoterodine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, Rasagiline may increase the hypotensive activities of Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Rasagiline is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Rasagiline may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Rasagiline.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Rasagiline.]
[L01XX08, pentostatin, Rasagiline may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of extrapyramidal symptoms can be increased when Rasagiline is combined with Perazine.]
[N04BC02, pergolide, Rasagiline may increase the hypertensive activities of Pergolide.]
[N05AB03, perphenazine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Rasagiline.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Phenazocine is combined with Rasagiline.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Rasagiline.]
[A10BA01, phenformin, Rasagiline may increase the hypoglycemic activities of Phenformin.]
[B01AA02, phenindione, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Phenindione.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Rasagiline.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Phenoperidine is combined with Rasagiline.]
[C04AX02, phenoxybenzamine, Rasagiline may increase the hypotensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Phenprocoumon.]
[A08AA01, phentermine, Rasagiline may increase the hypertensive activities of Phentermine.]
[V03AB36, phentolamine, Rasagiline may increase the hypotensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Rasagiline.]
[S01GA05, phenylephrine, Rasagiline may increase the hypertensive activities of Phenylephrine.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Rasagiline.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be increased when Phenytoin is combined with Rasagiline.]
[L04AB06, golimumab, The metabolism of Rasagiline can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Levofloxacin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C08CX01, mibefradil, Rasagiline may increase the hypotensive activities of Mibefradil.]
[N05AG02, pimozide, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Pimozide.]
[C07AA03, pindolol, Rasagiline may increase the hypotensive activities of Pindolol.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N05AC04, pipothiazine, The risk or severity of extrapyramidal symptoms can be increased when Rasagiline is combined with Pipotiazine.]
[N06BX03, piracetam, Rasagiline may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, Rasagiline may increase the hypotensive activities of Eprosartan.]
[A02BX03, pirenzepine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Piritramide is combined with Rasagiline.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Rasagiline.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J01MA11, grepafloxacin, The metabolism of Rasagiline can be decreased when combined with Grepafloxacin.]
[N02CX01, pizotyline, Rasagiline may increase the anticholinergic activities of Pizotifen.]
[C09CA04, irbesartan, Rasagiline may increase the hypotensive activities of Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Rasagiline is combined with Proxibarbal.]
[B01AC13, abciximab, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Alteplase.]
[A10BG02, rosiglitazone, Rasagiline may increase the hypoglycemic activities of Rosiglitazone.]
[A03AE01, alosetron, The metabolism of Rasagiline can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Rasagiline can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Rasagiline may increase the hypotensive activities of Polythiazide.]
[J05AE03, ritonavir, The metabolism of Rasagiline can be increased when combined with Ritonavir.]
[A10BH03, saxagliptin, Rasagiline may increase the hypoglycemic activities of Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Rasagiline is combined with Insulin lispro.]
[C07AB01, practolol, Rasagiline may increase the hypotensive activities of Practolol.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Rasagiline is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Rasagiline can be decreased when combined with Praziquantel.]
[C02CA01, prazosin, Rasagiline may increase the hypotensive activities of Prazosin.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Rasagiline.]
[P01BA03, primaquine, The metabolism of Rasagiline can be increased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Rasagiline can be increased when combined with Primidone.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[C01BA02, procainamide, Rasagiline may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Rasagiline.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Rasagiline.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N05AB04, prochlorperazine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Prochlorperazine.]
[N04AA04, procyclidine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The risk or severity of extrapyramidal symptoms can be increased when Rasagiline is combined with Promethazine.]
[C01BC03, propafenone, The metabolism of Rasagiline can be decreased when combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Rasagiline is combined with Propanidid.]
[A03AB05, propantheline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Periciazine.]
[N05CM06, propiomazine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, Rasagiline may increase the orthostatic hypotensive activities of Propofol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Rasagiline.]
[C07AA05, propranolol, Rasagiline may increase the hypotensive activities of Propranolol.]
[N02CC04, rizatriptan, The metabolism of Rizatriptan can be decreased when combined with Rasagiline.]
[B01AC09, epoprostenol, Rasagiline may increase the hypotensive activities of Epoprostenol.]
[N06AA11, protriptyline, Rasagiline may increase the serotonergic activities of Protriptyline.]
[R01BA02, pseudoephedrine, Rasagiline may increase the hypertensive activities of Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Rasagiline.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Rasagiline is combined with Dalfampridine.]
[A03AB15, diphemanil, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Rasagiline.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Rasagiline is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Rasagiline is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Rasagiline is combined with Pyrantel.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Mepyramine.]
[C01BA01, quinidine, The serum concentration of Rasagiline can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Rasagiline.]
[A02BA02, ranitidine, The metabolism of Rasagiline can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, Rasagiline may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Rasagiline is combined with Reserpine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Rasagiline can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Rasagiline is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Ritodrine is combined with Rasagiline.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Rasagiline is combined with Oxitriptan.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Rasagiline is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Rasagiline.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Salicylic acid is combined with Rasagiline.]
[S01FA02, scopolamine, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Rasagiline.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Rasagiline.]
[L01FA03, obinutuzumab, Rasagiline may increase the orthostatic hypotensive activities of Obinutuzumab.]
[J01GB08, sisomicin, Rasagiline may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Rasagiline may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Rasagiline may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, Rasagiline may increase the orthostatic hypotensive activities of Sotalol.]
[C03DA01, spironolactone, Rasagiline may increase the orthostatic hypotensive activities of Spironolactone.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Rasagiline.]
